Publications by authors named "G D'Agostino"

Growth differentiation factor 15, GDF15, and glucagon-like peptide-1 (GLP-1) analogues act through brainstem neurons that co-localise their receptors, GDNF-family receptor α-like (GFRAL) and GLP1R, to reduce food intake and body weight. However, their use as clinical treatments is partially hampered since both can also induce sickness-like behaviours, including aversion, that are mediated through a well-characterised pathway via the exterolateral parabrachial nucleus. Here, in mice, we describe a separate pathway downstream of GFRAL/GLP1R neurons that involves a distinct population of brain-derived neurotrophic factor (BDNF) cells in the medial nucleus of the tractus solitarius.

View Article and Find Full Text PDF

Olive mill wastewaters (OMWW) are characterized by a large concentration of pollutants, among which polyphenols represent a large part. This study investigated the effect of different dilutions of a culture medium enriched with olive-derived phenolic compounds on Chlorella vulgaris growth and its ability to degrade each one of them. In particular, polyphenols were precisely identified and quantified by HPLC-DAD analysis, showing high removal efficiency by C.

View Article and Find Full Text PDF

As the drive towards recycling electronic waste increases, demand for rapid and reliable analytical methodology to analyse the metal content of the waste is increasing, e.g. to assess the value of the waste and to decide the correct recycling routes.

View Article and Find Full Text PDF
Article Synopsis
  • The MITO-RT3/RAD trial was a Phase II study that evaluated the safety and effectiveness of stereotactic body radiotherapy (SBRT) for patients with oligometastatic ovarian cancer, focusing on those with lymph node disease.
  • Results showed a significant improvement in complete response (CR) rates, with 77.9% of lesions achieving CR, and an overall clinical benefit rate of 99.6% from 135 enrolled patients with 249 lesions across various institutions.
  • The trial indicated that SBRT has minimal toxicity, with 17% experiencing mild acute side effects, and it confirmed a strong correlation between CR and better progression-free survival (PFS)
View Article and Find Full Text PDF
Article Synopsis
  • - CXCR4 is a chemokine receptor that plays key roles in immune cell movement, organ development, and various diseases, including cancer and HIV-1 infection, with only one blocker, plerixafor, currently used clinically.
  • - Recent research shows that when activated by CXCL12, CXCR4 changes its structure, reducing membrane-bound units and forming larger immobile clusters necessary for cells to respond to chemical signals.
  • - Using molecular modeling, scientists discovered a compound, AGR1.137, that disrupts these CXCR4 clusters without interfering with CXCL12 binding, effectively blocking cellular response to chemical gradients in laboratory settings.
View Article and Find Full Text PDF